Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
The NHS Commissioning Board (operating under the name of NHS England and NHS Improvement) looks to establish an NHS Framework agreement (on behalf of NHS Trusts) for the supply of drugs licensed specifically to target epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer.\r
\r
\r
Ref: Tender C1485 Period of framework: 1st December 2020* to 30th November 2022 with an option to extend (at the Authority's discretion) for a further period (or periods) up to a total of 12 months (i.e. total possible framework duration of 36 months)\r
\r
All documents can be found at:health.atamis.co.uk
No supplier information available.